BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 13, 2021
Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech

...Capital Management led the financing, joined by Janus Henderson Investors, Adage Capital Management and undisclosed private investors.HemoShear...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant...
BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

...participation from BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

...series A round led by Epidarex, with participation from Evotec, VC Fonds Technologie and other private investors.TARGETSFAAH...
BioCentury | Sep 16, 2020
Deals

A deal for Grail could be Illumina’s next shot at diversifying

...an IPO on NASDAQ. Many prominent investors hold a stake in the company (see “Grail’s Private Investors”; “Dozens...
BioCentury | Sep 8, 2020
Finance

Algenex raises €7.4 million C round, looks to partner manufacturing platform with COVID-19 vaccine developers

...Columbus Life Science Fund II, a fund managed by Columbus Venture Partners, and other undisclosed private investors.Algenex...
BioCentury | Jul 13, 2020
Politics, Policy & Law

Cipla’s withdrawal of antibiotic marketing application latest sign of AMR market failure

...more than $500 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) and private investors...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...on Wednesday to raise up to $200 million. The biotech has amassed $520 million from private investors...
BioCentury | Jun 20, 2020
Finance

Survey: U.K. biotechs confident in fund-raising ability, unlikely to turn to government money

...in May 2020. Companies said this program was attractive because of the matched funding from private investors...
Items per page:
1 - 10 of 689
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 13, 2021
Finance

$40M series A sets up HemoShear to complete evolution from service play to clinical-stage biotech

...Capital Management led the financing, joined by Janus Henderson Investors, Adage Capital Management and undisclosed private investors.HemoShear...
BioCentury | Nov 19, 2020
Finance

Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more

Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by venBio Partners and Cormorant...
BioCentury | Nov 14, 2020
Product Development

Complete response for Sanofi’s rare anemia candidate; plus Sumitovant-Urovant, C4-Roche, IN8bio and Synendos

...participation from BERNINA BioInvest, Schroder Adveq, High-Tech Gründerfonds, Lichtsteiner Foundation, Essential Investments, Zürcher Kantonalbank and private investors...
BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

...series A round led by Epidarex, with participation from Evotec, VC Fonds Technologie and other private investors.TARGETSFAAH...
BioCentury | Sep 16, 2020
Deals

A deal for Grail could be Illumina’s next shot at diversifying

...an IPO on NASDAQ. Many prominent investors hold a stake in the company (see “Grail’s Private Investors”; “Dozens...
BioCentury | Sep 8, 2020
Finance

Algenex raises €7.4 million C round, looks to partner manufacturing platform with COVID-19 vaccine developers

...Columbus Life Science Fund II, a fund managed by Columbus Venture Partners, and other undisclosed private investors.Algenex...
BioCentury | Jul 13, 2020
Politics, Policy & Law

Cipla’s withdrawal of antibiotic marketing application latest sign of AMR market failure

...more than $500 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) and private investors...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...on Wednesday to raise up to $200 million. The biotech has amassed $520 million from private investors...
BioCentury | Jun 20, 2020
Finance

Survey: U.K. biotechs confident in fund-raising ability, unlikely to turn to government money

...in May 2020. Companies said this program was attractive because of the matched funding from private investors...
Items per page:
1 - 10 of 689